Answers are grounded in this paper and cite their sources.
// Johannes Meiser 1, 2, * , Lisa Kraemer 6, * , Christian Jaeger 2 , Henning Madry 3 , Andreas Link 4 , Philipp M. Lepper 5 , Karsten Hiller 2, 6, 7 and Jochen G. Schneider 2, 4, 8 1 Cancer Research UK Beatson Institute, Glasgow, UK 2 University of Luxembourg, Luxembourg Centre for Systems Biomedicine, Luxembourg City, Luxembourg 3 Saarland University Medical Centre, Centre of Experimental Orthopaedics, Homburg, Germany 4 Saarland University Medical Centre, Department of Internal Medicine II, Homburg, Germany 5 Saarland University Medical Centre, Department of Internal Medicine V, Homburg, Germany 6 Braunschweig Integrated Centre of Systems Biology, Technische Universität Braunschweig, Braunschweig, Germany 7 Department of Computational Biology of Infection Research, Helmholtz Centre for Infection Research, Braunschweig, Germany 8 Centre Hospitalier Emile Mayrisch, Esch, Luxembourg * These authors contributed equally to this work Correspondence to: Jochen G. Schneider, email: jg.schneider@outlook.com Keywords: itaconic acid; metabolism; sepsis; biomarker; inflammation; Immunology Received: February 16, 2017 Accepted: July 27, 2018 Published: August 14, 2018 ABSTRACT Itaconic acid is produced by mammalian leukocytes upon pro-inflammatory activation. It appears to inhibit bacterial growth and to rewire the metabolism of the host cell by inhibiting succinate dehydrogenase. Yet, it is unknown whether itaconic acid acts only intracellularly, locally in a paracrine fashion, or whether it is even secreted from the inflammatory cells at meaningful levels in peripheral blood of patients with severe inflammation or sepsis. The aim of this study was to determine the release rate of itaconic acid from pro-inflammatory activated macrophages in vitro and to test for the abundance of itaconic acid in bodyfluids of patients suffering from acute inflammation. We demonstrate that excretion of itaconic acid happens at a low rate and that it cannot be detected in significant amounts in plasma or urine of septic patients or in liquid from bronchial lavage of patients with pulmonary inflammation. We conclude that itaconic acid may serve as a pro-inflammatory marker in immune cells but that it does not qualify as a biomarker in the tested body fluids.
No takes yet. Share an insight, caveat, or question.
Meiser et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: